Guidelines for diagnosis and treatment (UK) – An Update

For the first time in ten years, the Guidelines for the Diagnosis and Treatment of Cholangiocarcinoma in the UK have been updated by a group of GI specialists*.

These are evidence based Guidelines, and were originally published in 2002. In this, the first update since that time, the specialists have based their work on a comprehensive review of the most recent literature, and have also used data from randomised controlled trials, systematic reviews, meta-analyses, cohort, prospective and retrospective studies.

The Guidelines were submitted to the British Society of Gastroenterology (BSG) mid 2011, and circulated for peer review nationally. Also, because the BSG wanted to have patient input, in September 2011 AMMF was asked to review the Guidelines from a layman/patient’s perspective, which we duly did. AMMF’s contribution is acknowledged in the introductory paragraph, ‘ … This manuscript has been developed with the support of The British Liver Trust and the UK cholangiocarcinoma charity, the Alan Morement Memorial Fund.’

Following approval by the British Society of Gastroenterology, the document was submitted for publication to the journal Gut. Gut then put it out to international reviewers, who came back with many pages of comments which had to be answered point by point. The final document has now been published by Gut and we are at last able to make it available on AMMF’s website.

The intention is that these Guidelines will be circulated to all specialist doctors and nurses in the field: hepatobiliary medicine/endoscopy/surgery, hepatology/GI physicians and surgeons, and GI cancer specialists.

This is a thorough, comprehensive overview of the situation regarding the diagnosis and treatment of cholangiocarcinoma in the UK today. To read it in full, click here

*The group: Shahid A. Khan, Brian R. Davidson, Robert Goldin, Nigel Heaton, John Karani, Stephen P. Pereira, William M. C. Rosenberg, Simon D. Taylor-Robinson, Paul Tait, Andrew V. Thillainayagam, Howard C. Thomas, Harpreet Wasan

Hepatology and Gastroenterology Section (S.A. Khan, S.D Taylor-Robinson, A. Thillainayagam, H.C. Thomas), Department of Medicine and Department of Histopathology (R. Goldin), Imperial College London, St Mary’s Hospital Campus, South Wharf Road, London W2 1NY, United Kingdom; Department of Oncology (H. Wasan), Imperial College London Hammersmith Hospital Campus, Du Cane Road, London W12 OHS; Department of Hepatobiliary Surgery (B.R. Davidson) and University College London Centre for Hepatology (S.P. Pereira, W.M.C. Rosenberg), Division of Medicine, University College London, Royal Free and University College Medical School, Pond Street, London, London, NW3 2QG; Department of Hepatobiliary and Pancreatic Surgery (N. Heaton, P. Karani), King’s College Hospital, Denmark Hill, London, SE5 9RS.

Bookmark and Share

27 November 2012

Cholangiocarcinoma

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

What is 9 + 6 ?
Please leave these two fields as-is:
IMPORTANT! To be able to proceed, you need to solve the following simple math (so we know that you are a human) :-)